GlaxoSmithKline CEO Andrew Witty has high hopes for an experimental pill his company is developing for anemia, as the drug could offer an oral alternative to injected EPO therapies.
The agency advisers weren't unanimous in backing GSK's follow-up to now-off-patent Advair, however.
China and India may top the list of fastest-growing pharma markets, but Brazil is no slouch, either. Drugmakers are wheeling and dealing there at an increasingly faster pace, as companies like Merck and Reckitt Benckiser join old-timers like Sanofi and GlaxoSmithKline in beefing up there.
The rise of vaccine manufacturers in emerging markets, particularly India, has helped depress the cost of immunization in recent years. Indian suppliers have rolled out vaccines at significant discounts and Western manufacturers have followed suit, slashing prices in poorer countries.
The arms race analogy for vaccines is rarely more apt than during a pandemic flu outbreak. Last week the U.S. touted a new, more streamlined approach to vaccine development. This week the virus raised the stakes with a surge of new cases that suggest it is adapting to human hosts.
GlaxoSmithKline took its Breo Ellipta program a step forward Wednesday afternoon, winning the endorsement of an FDA committee for approval of the once-daily treatment for patients with COPD.
Being the largest company by any number of measures--revenues, earnings, those kinds of yardsticks--is a good thing. Being the largest by number of employees is trickier, unless yours is also the largest by those other measures. As we have seen time and again in recent years in the pharma industry, having lots of employees and falling revenues is a formula that leads to layoffs. As a whole, the top 10 companies had fewer employees at the end of 2012 than at the end of 2011. Read the report >>
The ruling not only opens GSK to the Humana suit, which applies to its Medicare Advantage plans, but also to potential lawsuits from other insurers.
As GlaxoSmithKline gears up for an advisory committee meeting on Breo, the British drug giant can expect to face questions about the efficacy of the inhaled once-daily combo of fluticasone furoate (FF) and vilanterol (VI).
Once Avandia's heart risks were fully understood, the former blockbuster from GlaxoSmithKline, was tightly restricted in the U.S. and pulled from the European market. The diabetes drug was at the heart of the company's $3 billion settlement with federal authorities last year. Now, the FDA will take another hard look at the research on its side effects to see if there is something more the agency should do to limit its use.